Head and neck cancer encompasses a group of cancers that develop in the mouth, throat, voice box (larynx), nose, sinuses or salivary glands. Most are squamous cell carcinomas linked to tobacco use, alcohol consumption or human papillomavirus (HPV) infection. Early diagnosis by an ENT specialist significantly improves outcomes.
Head and neck cancers are classified by their site of origin. The major subsites include:
In Australia, approximately 5,500 people are diagnosed with head and neck cancer each year. While historically more common in older men who smoke and drink, HPV-related oropharyngeal cancer is increasingly seen in younger non-smoking adults.
Symptoms depend on where the cancer is located but commonly include:
Any of these symptoms persisting beyond three weeks should prompt an urgent GP referral to an ENT specialist. Early-stage cancers are far more treatable and have significantly better outcomes than late-stage disease.
The major risk factors for head and neck cancer include:
At Central Sydney ENT, our head and neck surgeons follow a structured diagnostic pathway:
Clinical examination: A thorough examination of the mouth, throat, neck, nose and ears. This includes flexible nasendoscopy (a thin camera passed through the nose) to visualise the throat and voice box directly in the clinic.
Biopsy: A tissue sample is obtained for histological examination. This may be performed in the clinic, under local anaesthesia, or as a formal examination under anaesthesia (panendoscopy) in hospital.
Imaging: CT scan of the head, neck and chest, MRI of the primary site, and PET-CT scan are used to determine the extent of disease and whether it has spread to lymph nodes or distant sites.
HPV testing: For oropharyngeal cancers, p16 immunohistochemistry is performed on the biopsy specimen to determine HPV status, which has important implications for treatment and prognosis.
Multidisciplinary team discussion: All cases are presented at a multidisciplinary head and neck tumour board meeting attended by ENT surgeons, radiation oncologists, medical oncologists, radiologists, pathologists, speech pathologists and dietitians to formulate the optimal treatment plan.
Treatment is tailored to the cancer's site, stage, HPV status and the patient's overall health. Options include:
Surgical excision is the primary treatment for many oral cavity cancers and selected throat, laryngeal and salivary gland cancers. This may include removal of the primary tumour, neck dissection to remove involved lymph nodes, and reconstructive surgery when needed. Minimally invasive approaches such as transoral robotic surgery (TORS) and transoral laser microsurgery are used where appropriate to reduce morbidity.
Radiation therapy uses high-energy beams to destroy cancer cells. It may be used as primary treatment (particularly for early laryngeal and nasopharyngeal cancers), as adjuvant treatment after surgery, or in combination with chemotherapy for advanced disease.
For advanced-stage cancers, chemotherapy (typically cisplatin) is given concurrently with radiotherapy to enhance the radiation effect. This is the standard treatment for many advanced oropharyngeal, hypopharyngeal and nasopharyngeal cancers.
Immune checkpoint inhibitors such as pembrolizumab and nivolumab are now available for recurrent or metastatic head and neck squamous cell carcinoma. These medications help the body's immune system recognise and attack cancer cells.
Our head and neck surgical oncologists, including Dr Alexander Zhang, Dr Arjuna Ananda, Dr Jareen Ebenezer and Dr Sam Hwang, work within multidisciplinary teams at major Sydney teaching hospitals to deliver comprehensive cancer care.
Seek an urgent referral to an ENT specialist if you experience:
Head and neck cancer is related to several other conditions managed at Central Sydney ENT:
Ask your GP for an urgent referral to Central Sydney ENT, or call our reception team directly.
Call (02) 9747 3199